Background {#Sec1}
==========

Perioperative fluid management has been recognized as an important factor in postoperative recovery following major abdominal surgery \[[@CR1], [@CR2]\]. There is evidence that either too little or too much fluid administration during the perioperative period was associated with organ dysfunction, delayed gastrointestinal (GI) function, and increased complication rates after surgery \[[@CR3]\]. However, optimal fluid management is difficult to achieve using standard parameters (e.g., heart rate \[HR\], blood pressure \[BP\], central venous pressure \[CVP\], or urine output) that poorly estimate preload and preload responsiveness \[[@CR4]\].

Goal-directed hemodynamic therapy (GDHT) was proposed by introducing different hemodynamic variables into a dynamic perspective of individual fluid loading with or without vasoactive substances to reach a predefined goal of optimal preload and/or oxygen delivery \[[@CR5]\]. An increasing numbers of studies of the effect of perioperative GDHT on postoperative recovery following major abdominal surgery are being done. However, the evidence for the beneficial effect of GDHT on postoperative recovery remains inconsistent. Several meta-analyses demonstrated that GDHT could decrease postoperative morbidity and mortality in patients undergoing major surgery \[[@CR1], [@CR6], [@CR7]\], but others suggested that the treatment benefit may be more marginal than previously believed \[[@CR8]--[@CR10]\]. More recent studies \[[@CR1], [@CR11]--[@CR14]\] have shown either equivalent or inferior outcomes in patients randomized to GDHT following major abdominal surgery. Therefore, we performed this up-to-date systematic review and meta-analysis to evaluate all available evidence regarding the effect of preoperative GDHT in comparison with conventional fluid therapy on postoperative recovery in adults undergoing major abdominal surgery.

Methods {#Sec2}
=======

We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines in reporting this systematic review and meta-analysis \[[@CR15]\]. A review protocol was written before this study was conducted.

Inclusion and exclusion criteria {#Sec3}
--------------------------------

The eligible studies of this systematic review and meta-analyses were identified using the patient, intervention, comparison, outcomes, study design strategy \[[@CR16]\]:*Patients/participants*: Adult patients (aged ≥16 years) undergoing major abdominal surgery were evaluated. Major abdominal surgery was defined using the Physiological and Operative Severity Score for the enUmeration of Mortality and Morbidity \[[@CR17]\]. Studies involving pediatric patients, nonsurgical patients, or postoperative patients with already-established sepsis or organ failure and undergoing late optimization were excluded.*Type of intervention*: Preoperative GDHT was used as the intervention treatment, which was defined as preoperative administration of fluids (initiated before surgery or in the intraoperative period and maintained in the postoperative period, or performed in the immediate postoperative period and lasting up to 6 h after surgery), with or without inotropes/vasoactive drugs, to increase blood flow (relative to control) against explicit measured goals, defined as cardiac output (CO), cardiac index, oxygen delivery (DO~2~), oxygen delivery index (DO~2~I), oxygen consumption, stroke volume (SV), dynamic measures of preload responsiveness (e.g., stroke volume variation \[SVV\], pulse pressure variation \[PPV\], and pleth variability index \[PVI\]), mixed venous oxygen saturation, oxygen extraction ratio, or lactate. Studies in which GDHT was limited to the preoperative period were excluded.*Type of comparator*: Conventional fluid administration strategies were used as control group, defined as that using the standard monitoring parameters (BP, HR, urine output, and CVP) to guide fluid therapy.*Types of outcomes*: Studies in which researchers reported postoperative complications, mortality, and GI function recovery outcomes (i.e., time to tolerate oral diet, time to first flatus, and time to first bowel movement) were included.*Types of studies*: Randomized controlled trials (RCTs), with or without blinding, were included. Data derived from letters, case reports, reviews, or cohort studies were excluded.

Search strategy and study selection {#Sec4}
-----------------------------------

A systematic search of MEDLINE, Embase, CINAHL, Scopus, the Cochrane Controlled Trials Register, and Cochrane Database of Systematic Reviews from inception to November 2016 was performed to identify relevant studies using the following search terms: "surgery," "fluid," "goal directed," "end point," "hemodynamic," "target," "goal," and "randomized controlled trials." Detailed search information used in MEDLINE is presented in [Appendix 1](#Sec18){ref-type="sec"}. No language restriction was placed on our search. Ongoing trials were searched in the ClinicalTrials.gov databased as well as in conference abstracts, which might provide results even though the trials have not been published yet. Furthermore, the reference lists of the identified reports, reviews, and other relevant publications were reviewed to find additional relevant trials. The reference lists of all eligible publications and reviews were scanned to identify additional studies. Two authors (YS and FC) independently screened and reviewed all titles and abstracts for eligibility. For abstracts that did not provide sufficient information to determine eligibility, full-length articles were retrieved. Agreement between the two authors for inclusion of screened articles was measured using weighted kappa, and disagreement on inclusion or exclusion of articles was resolved by consensus.

Data extraction {#Sec5}
---------------

Studies were reviewed and data were extracted independently by two authors (YS and FC) using a predesigned standard form, with any discrepancy being resolved by reinspection of the original article. The following data points were extracted: first author, year of publication, total number of patients, patients' characteristics, abdominal procedures, the GDHT strategy (goals, monitoring methods, and interventions). The primary endpoints of this review included long-term mortality (i.e., death in longest available follow-up), short-term mortality (i.e., death in the hospital or within 30 days after surgery), and overall complication rates (i.e., number of patients with complications after surgery). The secondary outcome was recovery of GI function, including time to toleration of an oral diet, time to first flatus, and time to first bowel movement. Authors were contacted for missing information about fluid management or data on postoperative recovery. If detailed information was not received, data from such studies were excluded from the present meta-analysis.

Risk-of-bias assessment {#Sec6}
-----------------------

The Cochrane Collaboration's tool \[[@CR18]\] for assessing risk of bias was applied independently by two authors. Risk of bias was assessed as high, low, or unclear for each of selection bias, performance bias, detection bias, attrition bias, and reporting bias. Information for judging the risk of bias was collected from all reports originating from one study, as well as from the protocol published in the registry, if applicable. Appropriate allocation to group assignment and concealment of randomization were considered more important than other domains for minimizing risk of bias in evaluating the effect of GDHT on postoperative recovery after major abdominal surgery, and the reviewers gave more importance to these domains when deciding on overall risk of bias. Agreement between the two reviewers on overall risk-of-bias assessment was determined using weighted kappa as well. Disagreements were resolved through discussion.

Grading quality of evidence {#Sec7}
---------------------------

The quality of evidence for each outcome was assessed according to Grading of Recommendations, Assessment, Development and Evaluations (GRADE) methods for risk of bias, inconsistency, indirectness, imprecision, and publication bias, and it was evaluated using GRADEPro software 3.6 (GRADE Working Group). These were classified as very low, low, moderate, or high \[[@CR19], [@CR20]\].

Statistical analysis {#Sec8}
--------------------

All statistical analyses were conducted using RevMan 5.1 (The Cochrane Collaboration, Oxford, UK) and Stata/SE software 10.0 (StataCorp, College Station, TX, USA). Meta-analysis was undertaken where data were sufficient. For continuous data, weighted mean differences (WMDs) with 95% CIs were calculated. If the 95% CI included 0, the difference between the GDHT and control groups was not considered statistically significant. When mean and SD values were not given, they were estimated from the median and SE or CI or from the IQR using the method described by Hozo et al. \[[@CR21]\]. Dichotomous data were analyzed by use of risk ratio (RR) with 95% CI. If the 95% CI around the RR did not include 1.0, the difference between the GDHT and control groups was assumed to be statistically significant. We assessed the included studies for functional equivalence, but we additionally used the Cochran chi-square *Q* and *I* ^2^ statistics to assess heterogeneity across studies. Heterogeneity was considered as either a *p* value \<0.05 or *I* ^2^ \> 25% \[[@CR22]\]. The use of either a fixed-effect or random-effect model was based on a combination of these methods.

The univariate meta-regression analyses were conducted when appropriate (i.e., number of studies \>10) to explore the potential heterogeneity according to type of monitoring technology, type of interventions, therapeutic goals, whether in context with enhanced recovery programs, and overall "fitness" of the patients (i.e., high- risk patients versus non-high-risk patients). High-risk patients were defined as patients with an American Society of Anesthesiologists physical status classification of III with two or more risk factors according to the risk index of Lee (i.e., high-risk type of surgery, ischemic heart disease, history of congestive heart failure, history of cerebrovascular disease, insulin therapy for diabetes, and preoperative serum creatinine \>2.0 mg/dl) \[[@CR7]\]. Moreover, prespecified subgroup analyses were conducted on the basis of these potential confounders to minimize heterogeneity and evaluate the effect of GDHT in the specific subpopulations. Additional sensitivity analyses were performed, including studies for colorectal surgical procedures, studies randomizing large-sample-size patients (defined as sample size ≥100), and studies judged to carry a low risk of bias. Finally, the influence of each study was evaluated on the basis of overall estimates by calculating random-effect pooled estimates, omitting each estimate one at a time \[[@CR23]\].

Publication bias was evaluated using Begg's funnel plots. Two formal tests---Begg's adjusted rank correlation and Egger's regression asymmetry test---were also used to assess publication bias \[[@CR24], [@CR25]\].

Results {#Sec9}
=======

There were 12,348 records for title and abstract screening. After applying inclusion and exclusion criteria, 12,188 citations were excluded because of duplication of published data, not reporting original research, or no human patients being involved. The remaining subset of 160 articles was gathered for further review. This group was evaluated in detail by each author to reach consensus on whether the articles met the inclusion criteria described above until full consensus was reached. Of this group, 115 articles were excluded because they were not RCTs, involved nonsurgical patients, did not evaluate the effect of GDHT, did not involve major abdominal surgery, did not use conventional fluid therapy as a control group, or were published only in letter or abstract form. A total of 45 RCTs were finally considered for this review (Fig. [1](#Fig1){ref-type="fig"}). The authors had perfect agreement in selecting the 45 studies using the stated eligibility criteria.Fig. 1Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram of study selection. *GDHT* Goal-directed hemodynamic therapy, *RCT* Randomized controlled trial

Study characteristics {#Sec10}
---------------------

The 45 RCTs \[[@CR1], [@CR11]--[@CR14], [@CR26]--[@CR65]\] yielded 6344 patients (Table [1](#Tab1){ref-type="table"}). Of those patients, 3406 received perioperative GDHT. Sample sizes ranged from 27 to 1994. All studies were reported between 1988 and 2015 in English-language journals.Table 1Study characteristics and overall risk of bias assessment for each studyTrial/author, year \[reference\]Number of patientsNature of surgeryGoal-directed hemodynamic therapyERP performedOverall risk of biasGoalMonitoring methodInterventionsBender et al., 1997 \[[@CR26]\]106Elective infrarenal aortic surgery or lower limb revascularizationCardiac index ≥2.8 L/minute/m^2^, SVR ≤1100 dyn/second/cm^5^, PAWP 8--14 mmHgPACFluids and inotropesNoHighBenes et al., 2010 \[[@CR27]\]120 (high-risk)Open major abdominal surgerySVV 10%, cardiac index 2.5--4.1 L/minute/m^2^, and MAP \>70 mmHgPulse contour analysis monitorFluids, inotropes, and vasopressorsNoLowBisgaard et al., 2013 \[[@CR28]\]64Open abdominal aortic surgeryOptimal SV, DO~2~I \>600 ml/minute/m^2^, HR \<100 beats/minutePulse contour analysis monitorFluids and inotropesNoLowBonazzi et al., 2002 \[[@CR29]\]100Open abdominal aortic surgerySVR ≤1450 dyn/second/cm^5^, PAOP 10--18 mmHg, cardiac index \>3 L/minute/m^2^, and DO~2~I \>600 ml/minute/m^2^PACFluids and inotropesNoUnclearBrandstrup et al., 2012 \[[@CR11]\]150Open and laparoscopic colorectal surgerySV 10%Esophageal DopplerFluidsYesLowBuettner et al., 2008 \[[@CR31]\]80Major abdominal surgerySPV \<10%Pulse contour analysis monitorFluidsNoLowBoyd et al., 1993 \[[@CR30]\]107 (high-risk)Major abdominal surgeryDO~2~I \>600 ml/minute/m^2^PACFluids and inotropesNoUnclearBundgaard-Nielsen et al., 2013 \[[@CR63]\]42Open radical prostatectomyOptimal SVEsophageal DopplerFluidsYesLowCohn et al., 2010 \[[@CR47]\]27Open colorectal surgeryStO~2~ \> 75%Near-infrared spectroscopyFluidsNoLowCorrea-Gallego et al., 2015 \[[@CR12]\]135Liver resectionSVV baselinePulse contour analysis monitorFluids and inotropesNoLowChalland et al., 2011 \[[@CR32]\]179 (56 high-risk)Major open or laparoscopic colorectal surgerySV 10%Esophageal DopplerFluidsYesLowConway et al., 2002 \[[@CR33]\]57Colorectal resectionSV 10%, FTc \>0.35Esophageal DopplerFluidsNoUnclearDonati et al., 2007 \[[@CR34]\]135 (high-risk)Major abdominal surgeryO~2~ER ≤27%Central line + arterial line samplingFluids and inotropesNoUnclearForget et al., 2010 \[[@CR35]\]82Major abdominal surgeryPleth variability index \<13%Pulse oximeterFluidsNoUnclearGan et al., 2002 \[[@CR36]\]100 (high-risk)Major open abdominal surgerySV 10%, FTc \>0.35Esophageal DopplerFluidsNoLowJammer et al., 2010 \[[@CR37]\]241Open colorectal surgeryCentral venous oxygen saturation \>75%Central lineFluidsNoLowJhanji et al., 2010 \[[@CR38]\]135Major gastrointestinal surgeryOptimal SVPulse contour analysis monitorFluids or fluids and inotropesNoLowJones et al., 2013 \[[@CR39]\]91Liver resectionOptimal SVPulse contour analysis monitorFluidsYes^a^UnclearLopes et al., 2007 \[[@CR40]\]33Major abdominal surgeryVariation in arterial pulse pressure \<10%Arterial line + monitoringFluids and inotropesNoLowMayer et al., 2010 \[[@CR41]\]60 (high-risk)Major abdominal surgerySVV 12%, cardiac index ≥2.5 L/minute/m^2^, SVI \>35 ml/m^2^Pulse contour analysis monitorFluids, inotropes, and vasopressorsNoUnclearMcKenny et al., 2013 \[[@CR62]\]101Major gynecologic surgeryOptimal SVEsophageal DopplerFluidsNoLowNoblett et al., 2006 \[[@CR42]\]103Open and laparoscopic colorectal surgeryFTc \>0.35, SVEsophageal DopplerFluidsYesUnclearPearse et al., 2014 \[[@CR1]\]734 (high-risk)Major abdominal surgeryOptimal SVPulse contour analysis monitorFluids and inotropesNoLowPearse et al. 2005 \[[@CR43]\]122 (high-risk)General, vascular, and urologic surgeryDO~2~I \>600 ml/minute/m^2^Pulse contour analysis monitorFluids and inotropesNoLowPestana et al., 2014 \[[@CR13]\]142Major gastrointestinal surgeryCardiac index ≥2.5 ml/minute/m^2^, MAP \>65 mmHgNoninvasive cardiac output monitorFluids, vasopressors, and inotropesNoLowPhan et al., 2014 \[[@CR14]\]100Colorectal surgeryFTc \>0.35, SVEsophageal DopplerFluidsYesUnclearPhillai et al., 2011 \[[@CR44]\]66Radical cystectomy for bladder cancerFTc \>0.35, SVEsophageal DopplerFluidsYesUnclearRamsingh et al., 2013 \[[@CR45]\]38 (high-risk)Open major abdominal surgerySVV \<12%Pulse contour analysis monitorFluids and inotropesNoLowSalzwedel et al., 2013 \[[@CR61]\]160Major abdominal surgeryPPV 10%, cardiac index \>2.5 ml/minute/m^2^Pulse contour analysis monitorFluids and inotropes, vasopressorsNoLowSandham et al., 2003 \[[@CR46]\]1994 (high-risk)Major abdominal, thoracic, vascular, or hip fracture surgeryDO~2~I 550--600 ml/minute/m^2^, cardiac index 3.5--4.5 ml/minute/m^2^, MAP \>70 mmHg, PAOP 18 mmHg, HR \<120 beats/minute, Hct \>27%PACFluids and inotropesNoLowScheeren et al., 2013 \[[@CR65]\]52 (high-risk)Major abdominal surgery, radical cystectomySVV 10%Pulse contour analysis monitorFluids and inotropesNoLowSenagore et al., 2009 \[[@CR48]\]64Laparoscopic colectomyFTc \>0.35, SVEsophageal DopplerFluidsYesUnclearShoemaker et al., 1988 \[[@CR50]\]88 (high-risk)Major abdominal surgery and other types of surgeryCO \>4.5 L/minute, DO~2~I \>600 mL/minute/m^2^, VO~2~ \> 170 ml/minute/m^2^PACFluids and inotropesNoLowSharkawy et al., 2013 \[[@CR49]\]59Major liver resectionFTc \>0.35, SV 10%Esophageal DopplerFluidsNoUnclearSrinivasa et al., 2012 \[[@CR51]\]85Open or laparoscopic colectomyFTc \>0.35, SVEsophageal DopplerFluidsYesLowSzakmany et al., 2005 \[[@CR52]\]45Major abdominal surgeryITBVI 850--950 ml/m^2^Pulse contour analysis monitorFluidsNoUnclearUeno et al., 1997 \[[@CR53]\]34Major liver resectionDO~2~I \>600 ml/minute/m^2^, cardiac index \>4.5 L/minute/m^2^, VO~2~ \> 170 ml/minute/m^2^PACFluids and inotropesNoHighValentine et al., 1998 \[[@CR54]\]120Abdominal aortic surgeryCardiac index ≥2.8 L/minute/m^2^, PCWP 8--15 mmHg, SVR ≤1100 dyn/second/cm^5^PACFluids and inotropesNoHighWilson et al., 1999 \[[@CR56]\]138 (high-risk)General surgery, vascular surgery, and urologic surgeryDO~2~I \>600 ml/minute/m^2^, PAOP 12 mmHg, Hb \>110 g/L, SaO~2~ \> 94%PACFluids and inotropesNoUnclearWakeling et al., 2005 \[[@CR55]\]128Colorectal resectionSV 10%, CVP did not rise by 10mmHg or moreEsophageal DopplerFluidsYesUnclearYu et al., 2010 \[[@CR57]\]299Gastrointestinal surgeryCentral venous lactate \<1.6 mmol/LCentral line samplingFluids and inotropesYesLowZakhaleva et al., 2013 \[[@CR64]\]74Major abdominal surgeryFTc \>0.35, SV 10%Esophageal DopplerFluidsYesLowZeng et al., 2014 \[[@CR60]\]60Abdominal cancer surgerySVVPulse contour analysis monitorFluids and inotropesNoUnclearZhang et al., 2012 \[[@CR58]\]60Open gastrointestinal surgeryPulse pressure variationPulse oximeterFluidsNoLowZheng et al., 2013 \[[@CR59]\]60 (high-risk)Open gastrointestinal surgeryCardiac index ≥2.5 L/minute/m^2^, SVI \>35 ml/m^2^, MAP \>65 mmHgPulse contour analysis monitorFluids and inotropesYesLow*Abbreviations: BP* Blood pressure, *CO* Cardiac output, *CVP* Central venous pressure, *DO* ~*2*~ *I* Oxygen delivery index, *ERP* Enhanced recovery protocol, *FTc* Corrected flow time, *Hct* Hematocrit, *Hb* Hemoglobin, *HR* Heart rate, *ITBVI* Intrathoracic blood volume index, *MAP* Mean arterial pressure, *O* ~*2*~ *ER* Oxygen extraction ratio, *PAC* Pulmonary arterial catheter, *PAOP* Pulmonary arterial occlusion pressure, *PAWP* Pulmonary arterial wedge pressure, *PCWP* Pulmonary capillary wedge pressure, *SPV* Systolic pressure variation, *StO* ~*2*~ Tissue blood oxygen saturation, *SV* Stroke volume, *SVI* Stroke volume index, *SVV* Stroke volume variation, *SVR* Systemic vascular resistance, *VO* ~*2*~ Oxygen consumption^a^ ERP performed only in study group

Bias risk was analyzed with the Cochrane tool. The methodological quality of included trials is presented in a summary graph (Fig. [2](#Fig2){ref-type="fig"}) and table (Additional file [1](#MOESM1){ref-type="media"}). A total of 26 studies (58%) \[[@CR1], [@CR3], [@CR11]--[@CR13], [@CR27], [@CR28], [@CR31], [@CR32], [@CR36]--[@CR38], [@CR40], [@CR43], [@CR45]--[@CR47], [@CR50], [@CR51], [@CR57]--[@CR59], [@CR61], [@CR62], [@CR64], [@CR65]\] were judged to carry a low risk of bias (Table [1](#Tab1){ref-type="table"}). Weighted kappa was calculated to examine agreement for each component and overall risk of bias assessment. The kappa statistics showed substantial agreement between the reviewers (Additional file [2](#MOESM2){ref-type="media"}).Fig. 2Review authors' judgments about each risk of bias item presented as percentages across all included studies

Eight trials \[[@CR26], [@CR29], [@CR30], [@CR46], [@CR50], [@CR53], [@CR54], [@CR56]\] used pulmonary arterial catheters for monitoring; fourteen trials \[[@CR3], [@CR11], [@CR14], [@CR32], [@CR33], [@CR36], [@CR42], [@CR44], [@CR48], [@CR49], [@CR51], [@CR55], [@CR62], [@CR64]\] used esophageal Doppler monitoring; fifteen trials \[[@CR3], [@CR12], [@CR27], [@CR28], [@CR31], [@CR38], [@CR39], [@CR41], [@CR43], [@CR45], [@CR52], [@CR59]--[@CR61], [@CR65]\] used self-calibrating/calibrated pulse contour analysis monitoring; and the remaining eight trials used other monitors, including arterial lines plus monitoring equipment \[[@CR40]\], central lines and arterial line sampling \[[@CR34], [@CR37], [@CR57]\], pulse oximeters \[[@CR35], [@CR58]\], and other noninvasive monitors \[[@CR13], [@CR47]\]. Three types of goals were used in the majority of included trials, including DO~2~I and/or cardiac index \[[@CR13], [@CR26], [@CR29], [@CR30], [@CR43], [@CR46], [@CR50], [@CR53], [@CR54], [@CR56], [@CR59]\], optimal SV \[[@CR1], [@CR11], [@CR28], [@CR32], [@CR33], [@CR36], [@CR38], [@CR39], [@CR42], [@CR44], [@CR48], [@CR49], [@CR51], [@CR55]\], and dynamic measures of preload responsiveness (e.g., PPV, SVV, PVI) \[[@CR12], [@CR27], [@CR31], [@CR35], [@CR40], [@CR41], [@CR45], [@CR52], [@CR58], [@CR60], [@CR61], [@CR65]\].

Meta-analyses {#Sec11}
-------------

### Long-term mortality {#Sec12}

Thirty-three trials \[[@CR1], [@CR11], [@CR14], [@CR26]--[@CR36], [@CR38]--[@CR43], [@CR46], [@CR48], [@CR50], [@CR52], [@CR53], [@CR56], [@CR57], [@CR60], [@CR62], [@CR64], [@CR65]\] provided data on long-term mortality, and further information was obtained from a previous meta-analysis \[[@CR8]\] for one study \[[@CR44]\]. The long-term mortality was 242 (8.1%) of 2959 in the GDHT group and 285 (9.9%) of 2888 in the control group, and the pooled RR of 0.80 showed that use of perioperative GDHT was barely associated with improved long-term survival after major abdominal surgery compared with the control group (95% CI 0.64--99, *p* = 0.04; *I* ^2^ = 4%) (Fig. [3a](#Fig3){ref-type="fig"}). The GRADE quality of evidence was judged to be moderate, downgraded for risk of bias.Fig. 3Meta-analysis and pooled risk ratio (RR) of the effect of perioperative goal-directed hemodynamic therapy (GDHT) on long-term mortality after major abdominal surgery and the influence analysis of individual studies on the pooled RR. Forest plots for (**a**) long-term mortality and (**b**) the influence of individual studies on the pooled RR

Subgroup analyses revealed that a statistically significant effect of GDHT in long-term mortality for high-risk patients (RR 0.57, 95% CI 0.36--0.89, *p* = 0.01; *I* ^2^ = 51%; number of studies \[*n*\] = 12 \[[@CR1], [@CR27], [@CR30], [@CR32], [@CR34], [@CR36], [@CR41], [@CR43], [@CR46], [@CR50], [@CR56], [@CR65]\]), patients using cardiac index and/or DO~2~I as therapeutic goals (RR 0.48, 95% CI 0.25--0.94, *p* = 0.03; *I* ^2^ = 60%; *n* = 9 \[[@CR13], [@CR26], [@CR29], [@CR30], [@CR43], [@CR46], [@CR50], [@CR53], [@CR56]\]), and patients using fluids and inotropes as interventions (RR 0.63, 95% CI 0.44--0.89, *p* = 0.008; *I* ^2^ = 32%; *n* =20 \[[@CR1], [@CR12], [@CR13], [@CR26]--[@CR30], [@CR34], [@CR38], [@CR40], [@CR41], [@CR43], [@CR46], [@CR50], [@CR53], [@CR56], [@CR57], [@CR60], [@CR65]\]) (Additional file [3](#MOESM3){ref-type="media"}). Meta-regression analyses did not find the significant effect of overall "fitness" of the patients, type of monitoring technology, type of intervention, therapeutic goals, and whether in context with enhanced recovery programs on our result (Additional file [4](#MOESM4){ref-type="media"}). No statistical difference was found when we analyzed studies for colorectal surgical procedures, studies randomizing large-sample-size patients, and studies carrying a low risk of bias (Additional file [3](#MOESM3){ref-type="media"}). The influence analyses showed that each study except one trial \[[@CR46]\] had a minor influence on the overall pooled RR. The statistical difference between the GDHT and control groups reached significance after this trial was omitted (RR 0.63, 95% CI 0.48--0.83, *p* = 0.001) (Fig. [3b](#Fig3){ref-type="fig"}). Neither Begg's adjusted rank correlation test (*p* = 0.10) nor Egger's regression asymmetry test (*p* = 0.93) was significant for mortality. A funnel plot is presented in Additional file [5](#MOESM5){ref-type="media"}.

### Short-term mortality {#Sec13}

Thirty-four studies \[[@CR1], [@CR11]--[@CR14], [@CR26]--[@CR36], [@CR38]--[@CR41], [@CR43], [@CR44], [@CR46]--[@CR48], [@CR50], [@CR52]--[@CR54], [@CR56], [@CR60], [@CR62], [@CR64], [@CR65]\] provided suitable data for analysis. The pooled short-term mortality was 153 (5.2%) of 2959 in the GDHT group and 203 (7.0%) of 2888 in the control group, and the RR was 0.75 (95% CI 0.61--0.91, *p* = 0.004; *I* ^2^ = 0%), showing a significant reduction in the GDHT group (Fig. [4a](#Fig4){ref-type="fig"}). The GRADE quality of evidence was judged to be moderate, downgraded for risk of bias.Fig. 4Meta-analysis and pooled risk ratio (RR) of the effect of perioperative goal-directed hemodynamic therapy (GDHT) on short-term mortality after major abdominal surgery and the influence analysis of individual studies on the pooled RR. Forest plots for (**a**) short-term mortality and (**b**) the influence of individual studies on the pooled RR

In subgroup analyses, we found that GDHT significantly reduced short-term mortality when a pulmonary arterial catheter was used for monitoring (RR 0.36, 95% CI 0.14--0.96, *p* = 0.04; *I* ^2^ = 68%; *n* = 7 \[[@CR26], [@CR29], [@CR30], [@CR46], [@CR50], [@CR53], [@CR56]\]), cardiac index and/or DO~2~I were used as therapeutic goals 2(RR 0.49, 95% CI 0.25--0.94, *p* = 0.03; *I* ^2^ = 55%; *n* = 9 \[[@CR13], [@CR26], [@CR29], [@CR30], [@CR43], [@CR46], [@CR50], [@CR53], [@CR56]\]), fluids and inotropes were used as interventions (RR 0.65, 95% CI 0.47--0.89, *p* = 0.007; *I* ^2^ =19%; *n* = 20 \[[@CR1], [@CR12], [@CR13], [@CR26]--[@CR30], [@CR34], [@CR38], [@CR40], [@CR41], [@CR43], [@CR46], [@CR50], [@CR53], [@CR56], [@CR57], [@CR60], [@CR65]\]), outside of enhanced recovery programs (RR 0.71, 95% CI 0.53--0.94, *p* \< 0.0001; *I* ^2^ = 11%; *n* = 25 \[[@CR1], [@CR12], [@CR26]--[@CR28], [@CR31], [@CR33]--[@CR35], [@CR38], [@CR40], [@CR41], [@CR43]\]), and for high-risk patients (RR 0.73, 95% CI 0.58--0.91, *p* = 0.09; *I* ^2^ = 39%; *n* = 12 \[[@CR1], [@CR27], [@CR30], [@CR32], [@CR34], [@CR36], [@CR41], [@CR43], [@CR46], [@CR50], [@CR56], [@CR65]\]) (Additional file [3](#MOESM3){ref-type="media"}). Again, meta-regression analysis failed to identify the significant factors contributing this result (Additional file [6](#MOESM6){ref-type="media"}). No statistical difference was found when we analyzed studies for colorectal surgical procedures, studies randomizing large-sample-size patients, and studies carrying a low risk of bias (Additional file [3](#MOESM3){ref-type="media"}). The influence analyses showed each study had no substantial influence on the overall pooled RR (Fig. [4b](#Fig4){ref-type="fig"}). A funnel plot is presented in Additional file [7](#MOESM7){ref-type="media"}. Neither Begg's adjusted rank correlation test (*p* = 0.08) nor Egger's regression asymmetry test (*p* = 0.48) showed evidence of publication bias regarding short-term mortality.

### Overall complication rates {#Sec14}

Thirty-one trials \[[@CR11]--[@CR13], [@CR26]--[@CR28], [@CR32]--[@CR34], [@CR36]--[@CR39], [@CR41]--[@CR43], [@CR47], [@CR49], [@CR50], [@CR53]--[@CR57], [@CR61], [@CR62], [@CR64], [@CR65]\] reported suitable data on number of patients with complications. The pooled RR of 0.76 showed reduced overall complication rates after major abdominal surgery in the GDHT group compared with the control group (95% CI 0.68--0.85, *p* \< 0.0001; *I* ^2^ = 38%) (Fig. [5a](#Fig5){ref-type="fig"}). The GRADE quality of evidence was judged to be low, downgraded for risk of bias and inconsistency.Fig. 5Meta-analysis and pooled risk ratio (RR) of the effect of perioperative goal-directed hemodynamic therapy (GDHT) on overall complication rates after major abdominal surgery and the influence analysis of individual studies on the pooled RR. Forest plots for (**a**) overall complication rates and (**b**) the influence of individual studies on the pooled RR

Subgroup analyses showed a significant reduction in GDHT group in those studies using pulse contour analysis monitoring (RR 0.75, 95% CI 0.64--0.87, *p* = 0.003; *I* ^2^ = 33%; *n* = 10 \[[@CR1], [@CR12], [@CR27], [@CR28], [@CR38], [@CR39], [@CR41], [@CR43], [@CR61], [@CR65]\]), using esophageal Doppler monitoring (RR 0.75, 95% CI 0.58--0.95, *p* = 0.002; *I* ^2^ = 53%; *n* = 10 \[[@CR11], [@CR14], [@CR32], [@CR33], [@CR36], [@CR42], [@CR51], [@CR55], [@CR62], [@CR64]\]), using fluids and inotropes as interventions (RR 0.76, 95% CI 0.66--0.86, *p* \< 0.0001; *I* ^2^ = 36%; *n* = 19 \[[@CR1], [@CR12], [@CR13], [@CR26]--[@CR28], [@CR34], [@CR38], [@CR40], [@CR41], [@CR43], [@CR50]\]), using cardiac index and/or DO~2~I (RR 0.78, 95% CI 0.63--0.97, *p* = 0.03; *I* ^2^ = 18%; *n* = 7 \[[@CR1], [@CR26], [@CR43], [@CR53], [@CR54], [@CR56]\]), or optimal SV (RR 0.80, 95% CI 0.69--0.93, *p* = 0.0002; *I* ^2^ = 40%; *n* = 14 \[[@CR1], [@CR10], [@CR11], [@CR14], [@CR28], [@CR32], [@CR33], [@CR36], [@CR38], [@CR39], [@CR42], [@CR55], [@CR62], [@CR64]\]) or dynamic measures of preload responsiveness (RR 0.64, 95% CI 0.52--0.79, *p* \< 0.0001; *I* ^2^ = 16%; *n* = 6 \[[@CR12], [@CR27], [@CR40], [@CR41], [@CR61], [@CR65]\]) as therapeutic goals, as well as for either high-risk patients (RR 0.65, 95% CI 0.56--0.76, *p* \< 0.0001, *I* ^2^ = 28%; *n* = 10 \[[@CR1], [@CR27], [@CR32], [@CR34], [@CR36], [@CR41], [@CR43], [@CR50], [@CR56], [@CR65]\]) or non-high-risk patients (RR 0.84, 95% CI 0.74--0.96, *p* = 0.08; *I* ^2^ = 29%; *n* = 21 \[[@CR11]--[@CR14], [@CR26], [@CR28], [@CR33], [@CR37]--[@CR40], [@CR42], [@CR47], [@CR51], [@CR53]--[@CR55], [@CR57], [@CR61], [@CR62], [@CR64]\]) (Additional file [3](#MOESM3){ref-type="media"}). Meta-regression analyses did not reveal a significant effect of all predefined confounders on overall complication rates (Additional file [8](#MOESM8){ref-type="media"}). Additionally, a statistically significant effect of GDHT on overall complication rates was found when we pooled all studies carrying to a low risk of bias (RR 0.78, 95% CI 0.70--0.87, *p* \< 0.0001; *I* ^2^ = 31% ; *n* = 20 \[[@CR1], [@CR11]--[@CR13], [@CR27], [@CR28], [@CR32], [@CR36]--[@CR38], [@CR40], [@CR43], [@CR47], [@CR50], [@CR51], [@CR57], [@CR61], [@CR62], [@CR64], [@CR65]\]) and studies randomizing large-sample-size patients (RR 0.79, 95% CI 0.69--0.89, *p* = 0.002; *I* ^2^ = 43% ; *n* = 19 \[[@CR1], [@CR11]--[@CR14], [@CR26], [@CR27], [@CR32], [@CR34], [@CR36]--[@CR38], [@CR42], [@CR43], [@CR54]--[@CR57], [@CR62]\]) (Additional file [3](#MOESM3){ref-type="media"}). The influence analyses showed each study had no substantial influence on the overall pooled RR (Fig. [5b](#Fig5){ref-type="fig"}). Begg's test and Egger's test excluded the presence of publication bias (*p* = 0.08 and *p* = 0.06, respectively). A funnel plot is presented in Additional file [9](#MOESM9){ref-type="media"}.

### GI function recovery {#Sec15}

Perioperative GDHT shortened the time to first flatus (WMD −0.40 days, 95% CI −0.72 to −0.08, *p* \< 0.0001; *I* ^2^ = 74%; *n* = 10 \[[@CR13], [@CR32], [@CR42], [@CR44], [@CR55], [@CR58]--[@CR61], [@CR64]\]) and time to toleration of an oral diet (WMD −0.74 days, 95% CI −1.44 to −0.03, *p* \< 0.0001; *I* ^2^ = 92%; *n* = 9 \[[@CR32], [@CR36], [@CR42], [@CR44], [@CR45], [@CR55], [@CR59], [@CR62], [@CR64]\]), but it did not shorten the time to first bowel movement (Fig. [6](#Fig6){ref-type="fig"}). The GRADE quality of evidence was judged to be low, downgraded by risk of bias and inconsistency.Fig. 6Meta-analysis and pooled weighted mean differences (WMDs) of the effect of perioperative goal-directed hemodynamic therapy (GDHT) on (**a**) time to first flatus pass, (**b**) time to first bowel movement, and (**c**) time to toleration of an oral diet after major abdominal surgery and the influence analysis of individual studies on the WMD. *Left side* shows Forest plots, and *right side* shows the influence of individual studies on the pooled estimates

Subgroup analyses based on the type of monitoring and therapeutic goals were not performed, owing to the limited number of studies. A statistically significant effect of GDHT was observed on time to toleration of an oral diet when we pooled studies for non-high-risk patients (WMD −0.83 days, 95% CI −1.51 to −0.14, *p* = 0.03; *I* ^2^ = 59%; *n* = 6 \[[@CR42], [@CR44], [@CR45], [@CR55], [@CR62], [@CR64]\]) and on time to first flatus pass for non-high-risk patients (WMD −0.41 days, 95% CI −0.80 to −0.01, *p* = 0.04; *I* ^2^ = 71%; *n* = 8 \[[@CR13], [@CR42], [@CR44], [@CR55], [@CR58], [@CR60], [@CR61], [@CR64]\]) and patients using fluids and inotropes as interventions (WMD −0.45 days, 95% CI −0.83 to −0.06, *p* \< 0.0001; *I* ^2^ = 64%; *n* = 4 \[[@CR13], [@CR59]--[@CR61]\]). No significant difference between the GDHT and control groups was found by sensitivity analysis restricting studies for colorectal surgical procedures, studies randomizing large-sample-size patients, and studies carrying a low risk of bias. The influence analyses showed that each study had no substantial influence on the overall pooled estimates, except for one trial regarding the time to first bowel movement. After we omitted this study, the difference in the time to first bowel movement reached statistical significance (WMD −0.28 days, 95% CI −0.43 to −0.13, *p* = 0.01) (Fig. [6](#Fig6){ref-type="fig"}).

Begg's test and Egger's test revealed no evidence of publication bias regarding time to first flatus (*p* = 1.00 and *p* = 0.48, respectively), time to first bowel movement (*p* = 0.91 and *p* = 0.19, respectively), or time to toleration of an oral diet (*p* = 0.28 and *p* = 0.46, respectively). A funnel plot is presented in Additional file [10](#MOESM10){ref-type="media"}.

Discussion {#Sec16}
==========

In this systematic review and meta-analysis, we found that perioperative GDHT improved survival, reduced overall complication rates, and facilitated GI functional recovery as demonstrated by shortening the time to first flatus pass and the time to toleration of an oral diet compared with conventional fluid therapy when all studies were considered. However, we did not identify the beneficial effects of GDHT on mortality and GI function when we restricted the analysis to higher-quality and large-sample-size studies; thus, future studies should be adequately powered and methodologically rigorous enough to confirm a clinically relevant effect in this area.

GDHT is currently recommended in the context of enhanced recovery programs, especially for moderate- to high-risk patients \[[@CR7]\]. High-risk patients tend to have an increased stress response to surgical aggression, increased oxygen demand, and reduced physiological reserves to deal with the metabolic requirements of the perioperative period. Strategies to maintain DO~2~ and minimize splanchnic hypoperfusion have been advocated to improve postoperative morbidity for high-risk surgical patients \[[@CR66]\]. In our subgroup analyses, we identified high-risk patients as a group that may potentially benefit from GDHT. However, the results of our subgroup analysis indicated that GDHT is beneficial mainly when used outside enhanced recovery programs. The potential explanation is that enhanced recovery programs emphasize the avoidance of bowel preparation, minimize fasting, and use preoperative carbohydrate loading \[[@CR67]\]. As a result, patients are less likely to be fluid-depleted during surgery and thus may not benefit as much from targeted fluid administration.

Many different GDHT strategies have been studied in the clinical setting. However, there is no clear consensus about the most effective or the most appropriate method of monitoring. One would suggest that the use of CO monitoring to guide administration of intravenous fluids coupled with inotropic drugs as part of a hemodynamic therapy algorithm, which has been shown to modify inflammatory pathways and improve tissue perfusion and oxygenation \[[@CR68]\]. In our subgroup analysis, we found that GDHT using cardiac index/DO~2~I as goals and using fluids and inotropes as interventions was associated with reductions in mortality and morbidity following major abdominal surgery. However, the meta-regression analyses did not reveal any significant effect of those confounders contributing to overall results regarding mortality and morbidity after major abdominal surgery. Therefore, future studies are needed to provide evidence supporting various goals and methods of monitoring.

With a number of recently published trials on this topic, this report is the most up-to-date analysis of the effects of GDHT on recovery after major abdominal surgery and is based on a comprehensive search strategy. This systematic review included eight high-quality studies \[[@CR28], [@CR37], [@CR38], [@CR43], [@CR46], [@CR50], [@CR57], [@CR58]\] that were not identified in the most recently published meta-analysis \[[@CR69]\], as well as two newly published studies \[[@CR1], [@CR12]\]. Moreover, we also included 12 studies \[[@CR26], [@CR30], [@CR34], [@CR39], [@CR41], [@CR47]--[@CR49], [@CR52]--[@CR54], [@CR56]\] that were excluded from the previous meta-analyses. Our findings support results of previous meta-analyses either for all types of surgery \[[@CR8]\] or following major abdominal surgery \[[@CR70]\].

There are some notable limitations of this review; therefore, the results should be interpreted with caution. Although our systematic review was focused on major abdominal procedures, owing to the unique nature of physiological change, we tried to attenuate the divergent effects of a heterogeneous population \[[@CR71]\]. However, the risk-benefit balance may be varied between the surgical procedures on the basis of the degree and duration of physiological stress. First, the results of sensitivity analysis restricted to studies with colorectal surgical procedures did not show the positive effect of GDHT on mortality, morbidity, and GI function recovery. Second, the GDHT strategy is quite complex and varied between trials, including fluid management, monitoring methods, therapeutic goals, and perioperative care environment. None of the included studies mentioned evaluating the effect of a single, clearly defined intervention, and analyzing data from some of the included trials using potential "nonoptimal" regimens might have impacted the results of our meta-analysis. Although our meta-regression analysis did not reveal a statistically significant influence of those confounders on overall results, the possibility of the regimen of GDHT that may be efficacious for postoperative recovery could not be excluded. Third, the quality of outcome data reported in the included studies was variable. Although the subgroup and sensitivity analyses could reduce the heterogeneity, not all planned subgroup and sensitivity analyses could be performed, owing to insufficient suitable data reported. Thus, the observed statistical heterogeneity in certain analyses could not always be ensured. Moreover, outcome measures were not consistent across all studies, and only relevant data from included trials could be considered for meta-analysis because of the limitation of pooled analysis. Although return of GI function is considered a meaningful outcome following abdominal surgery, only 13 of the 45 included trials provided data on this outcome. In addition, a specific analysis of complications was not performed, owing to the varied definitions between studies. Fourth, about half of the included studies had small sample sizes (\<100), which may lack statistical power to detect a clinically important difference in mortality. The sensitivity analysis when we restricted it to studies with higher methodological quality and studies with larger sample size did not confirm the results obtained. Finally, as with any meta-analysis, publication bias could not be excluded. Although Begg's test and Egger's test were conducted in this analysis and the results indicated no significant evidence for publication bias for each outcome, absence of significant asymmetry does not mean that publication bias was absent \[[@CR72]\].

Conclusions {#Sec17}
===========

This systematic review of available evidence suggests that the use of perioperative GDHT could improve postoperative recovery following major abdominal surgery, as demonstrated by a reduction of postoperative morbidity, improvement of survival, and earlier return of GI function. However, the most effective GDHT strategy remains unclear, and future adequately powered, high-quality RCTs are therefore needed to address this issue.
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Additional file 1:Risk of bias summary: review authors' judgments about each risk-of-bias item for each included study. (PDF 341 kb) Additional file 2:Weighted kappa measurements to assess agreement between reviewers in rating quality of methodology of included trials. (PDF 48 kb) Additional file 3:Results of subgroup analysis and sensitivity analyses for mortality and overall complication rates. *RR* Risk ratio, *CI* 95% Confidence interval, *ERP* Enhanced recovery protocol, *N* Number of studies, *n* Number of participants, *PAC* Pulmonary arterial catheter, *OEDM* Esophageal Doppler monitor, *CI\#* Cardiac index, *DO* ~*2*~ *I* Oxygen delivery index, *SV* Stroke volume, *SVV* Stroke volume variation. (1) Self-calibrating/calibrated pulse contour analysis monitor for example, Vigileo/Flotrac, LiDCO, PiCCO. (2) Arterial line monitoring equipment, central line and arterial line sampling, pulse oximeter, and other noninvasive monitors. (3) Pulse pressure variation (PPV), variation in arterial pulse pressure, and pleth variability index (PVI). (4) Mixed venous oxygen saturation, oxygen extraction ratio, or lactate. \* Statistically significant. (DOCX 20 kb) Additional file 4:Meta-regression analysis for long-term mortality based on type of patients (high-risk versus non-high-risk), type of monitoring used, type of interventions (fluids versus fluids and inotropes), therapeutic goals, and whether in context with enhanced recovery programs (ERPs). *RR* Risk ratio. (PDF 100 kb) Additional file 5:Begg's publication funnel plots on long-term mortality. *RR* Risk ratio. (PDF 127 kb) Additional file 6:Meta-regression analysis for short-term mortality. *ERP* Enhanced recovery program. (PDF 99 kb) Additional file 7:Publication funnel plots for short-term mortality. *RR* Risk ratio. (PDF 82 kb) Additional file 8:Meta-regression analysis for overall complication rates. *RR* Risk ratio, *ERP* Enhanced recovery program. (PDF 18 kb) Additional file 9:Begg's publication funnel plots on overall complication rates. *RR* Risk ratio. (PDF 128 kb) Additional file 10:Begg's publication funnel plots on time to first flatus pass (a), time to bowel movement (**b**), and time to tolerate oral diet (**c**). *WMD* Weighted mean difference. (PDF 54 kb)
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MEDLINE search strategy {#Sec19}
-----------------------

exp Fluid Therapy/

exp Body Fluids/

exp Echocardiography, Doppler/

exp Echocardiography, Transesophageal/

exp Ultrasonography, Doppler/

exp Cardiac Output/

exp Monitoring, Intraoperative/

exp Blood Flow Velocity/

exp Hemodynamics/

exp Stroke Volume/

exp Blood Pressure/

exp Pulmonary Artery/

exp Catheterization, Swan-Ganz/

exp Thermodilution/

exp Monitoring, Physiologic/

exp Pulse/

exp Intraoperative Care/or exp Intraoperative Period/

exp Oximetry/

Oxygen/or exp Oxygen Consumption/

exp Critical Care/

exp Biological Oxygen Demand Analysis/

exp Vascular Access Devices/

exp Arterial Pressure/

exp Central Venous Catheters/

exp Venous Pressure/

exp Manometry/

exp Models, Cardiovascular/

exp Cardiography, Impedance/

exp Cardiopulmonary Resuscitation/

exp Plethysmography, Impedance/or Plethysmography/

exp Heart Function Tests/

exp Indicator Dilution Techniques/

exp Radioisotope Dilution Technique/

exp Lithium Chloride/

exp Microdialysis/

exp Colloids/

exp Heart Rate/

exp Aorta/

exp Spectrum Analysis/

exp Spectroscopy, Near-Infrared/

exp Electric Impedance/

goal directed therapy.tw.

goal.tw.

exp Carbon Dioxide/

exp Pulsatile Flow/

exp Cardiac Volume/

exp Cardiac Output, Low/

exp Cardiac Output, High/

exp Diagnostic Techniques, Cardiovascular/

exp Plasma Substitutes/

1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50

exp Intestinal Mucosa/

exp Gastric Mucosa/

exp Splanchnic Circulation/

exp abdominal aortic surgery/or exp anastomosis, roux-en-y/or exp appendectomy/or exp biliary tract surgical procedures/or exp biliopancreatic diversion/or exp colectomy/or exp cystectomy/or exp endoscopy, digestive system/or exp enterostomy/or exp fundoplication/or exp gastrectomy/or exp gastroenterostomy/or exp gastropexy/or exp gastroplasty/or exp gastrostomy/or exp hemorrhoidectomy/or exp hepatectomy/or exp jejunoileal bypass/or exp liver transplantation/or exp pancreas transplantation/or exp pancreatectomy/or exp pancreaticoduodenectomy/or exp pancreaticojejunostomy/or exp peritoneovenous shunt/

exp Abdomen/

exp Laparoscopy/or exp Hand-Assisted Laparoscopy/

exp Laparotomy/

exp Colostomy/

exp Ileostomy/

exp Colonic Pouches/

exp Proctocolectomy, Restorative/

intermediate risk patients.mp.

high risk patients.mp.

abdominal surgery.mp.

52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65

51 and 66

exp Randomized Controlled Trial/

67 and 68

exp = explod

BP

:   Blood pressure

CO

:   Cardiac output

CVP

:   Central venous pressure

DO~2~

:   Oxygen delivery

DO~2~I

:   Oxygen delivery index

ERP

:   Enhanced recovery protocol

FTc

:   Corrected flow time

GDHT

:   Goal-directed hemodynamic therapy

GI

:   Gastrointestinal

GRADE

:   Grading of Recommendations, Assessment, Development and Evaluations

Hb

:   Hemoglobin

Hct

:   Hematocrit

HR

:   Heart rate

ITBVI

:   Intrathoracic blood volume index

MAP

:   Mean arterial pressure

O~2~ER

:   Oxygen extraction ratio

PAC

:   Pulmonary arterial catheter

PAOP

:   Pulmonary arterial occlusion pressure

PAWP

:   Pulmonary arterial wedge pressure

PCWP

:   Pulmonary capillary wedge pressure

PPV

:   Pulse pressure variation

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-Analyses

PVI

:   Pleth variability index

RCT

:   Randomized controlled trial

RR

:   Risk ratio

SPV

:   Systolic pressure variation

StO~2~

:   Tissue blood oxygen saturation

SV

:   Stroke volume

SVI

:   Stroke volume index

SVR

:   Systemic vascular resistance

SVV

:   Stroke volume variation

VO~2~

:   Oxygen consumption

WMD

:   Weighted mean difference
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